Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Clinical trials news

Show

From To
New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, as study presented at the recent ICAAC conference heard.

Published
09 September 2014
From
HIVandhepatitis.com
Racial/ethnic disparities in HIV medical studies examined by researchers

Social/behavioral intervention vastly increased the number of African American and Latino individuals living with HIV/AIDS who enrolled in HIV/AIDS medical studies, a study has found. Nine out of 10 participants who were found eligible for studies decided to enroll, compared to zero participants among a control group.

Published
08 July 2014
From
Science Daily
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily formulation of raltegravir (Isentress)

Merck (MSD) today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Raltegravir combines high potency with low toxicity but its more widespread use has been held back by its needing to be taken twice a day.

Published
06 June 2014
From
Merck
Mystery around drug adherence still plagues medical literature

The randomized controlled trial, or RCT, represents the gold standard of interventional studies of new drugs. But how reliable are the results when it remains unknown whether subjects in the trial actually took their medicines at all? A 2007 analysis found that only 33% of 192 papers describing RCTs of oral therapies for six chronic diseases disclosed adherence results.

Published
13 May 2014
From
Nature Medicine
Thanks for Nothing: iPrEX Volunteers Shut Out of PrEP’s Success

The benefits of the iPrEX trial have been localized - most volunteers in Peru, Ecuador, Brazil, Thailand and South Africa no longer have access to the drug.

Published
06 May 2014
From
Poz
PROUD UK PrEP study completes enrolment – first data give participants' background and risk factors

The pilot stage of the PROUD study – the UK's study of HIV pre-exposure prophylaxis (HIV-negative people taking HIV drugs to prevent HIV) in gay

Published
09 April 2014
By
Gus Cairns
Very different levels of PrEP uptake and adherence in three US cities, demonstration project finds

One of the first studies of open-label pre-exposure prophylaxis (PrEP) for at-risk gay men in three US cities shows that although the proportion of those initially offered or

Published
17 March 2014
By
Gus Cairns
Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation

An oral combination therapy of two antiretroviral drugs, the non-nucleoside rilpivirine (Edurant, also in Eviplera/Complera) and the new integrase inhibitor GSK1265744 (744), was at least as effective as

Published
08 March 2014
By
Gus Cairns
Raltegravir has the edge over two protease inhibitors in three-drug comparison study

In a head-to-head comparison of three drugs presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) on Wednesday, the integrase inhibitor raltegravir (Isentress) proved to

Published
07 March 2014
By
Gus Cairns
Spanish HIV Researcher Faces €210000 Fine Over Unauthorized Clinical Trial

A Spanish HIV/AIDS researcher is facing a hefty fine for violating clinical trial regulations. Vicente Soriano, a well-known clinical researcher with hundreds of publications to his name, is liable for €210,000 for conducting a clinical trial without approval from the Spanish Agency for Medicines and Health Products, failing to obtain insurance for the trial, and informing participants he had his hospital's ethical approval when he did not.

Published
31 January 2014
From
Science
← First12345...12Next →

Filter by country